Document 2711
 DOCN  M94A2711
 TI    Evaluation of Vironostika HIV Uni-Form II EIA, a third generation assay.
 DT    9412
 AU    Vercauteren G; Mangelschois M; van der Groen G; Institute of Tropical
       Medicine, Department Infection & Immunity,; Antwerpen, Belgium.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):242 (abstract no. PB0397). Unique
       Identifier : AIDSLINE ICA10/94369864
 AB    OBJECTIVE: To evaluate the performance of a new third generation enzyme
       immunoassay (EIA). METHODS: A panel of 412 aliquoted samples stored at
       -20 degrees C including samples of African (14%), European (76%) and
       other or unknown origin (10%) was tested on the Vironostika HIV Uni-Form
       II EIA (Organon Teknika Boxtel, The Netherlands). The prevalence for
       HIV-1 and HIV-2 antibody in this panel was 10.4% and 2.2% respectively.
       Additionally 4 HIV-1 seroconversion panels (PRB914, PRB916, PRB917,
       PRB918) from BBI were tested. These results were compared with 8
       different EIA's currently used in Europe. RESULTS: All known HIV-1 (43)
       and HIV-2 (9) positive samples were detected with the EIA evaluated.
       Five sera (5/359) remained repeatedly false reactive. These samples
       belonged to patients with a history of malaria (2) an elevated
       triglyceride (2) and with cystes of Entamoeba coli (1). The specificity
       for this panel was 98.6%, however the results obtained on fresh taken
       and frozen routine samples in Belgium (n = 120) (data not shown) gave a
       specificity of 100%. The Vironostika HIV-Uni-Form II EIA performed
       significantly better on the early seroconversion panels than the
       Vironostika HIV mixt EIA, and equally well compared to the Abbott
       recombinant 3rd generation EIA HIV-1+2. CONCLUSIONS: In this evaluation
       using frozen serum samples, the sensitivity of the Vironostika HIV
       Uni-Form II assay was 100% and the specificity 98.6%. HIV antibodies
       were detected as early with the HIV Uni-Form II EIA as with the Abbott
       HIV-1+2 EIA 3rd generation for the early seroconversion panels tested.
 DE    AIDS Serodiagnosis/*INSTRUMENTATION  Comparative Study  Human  HIV
       Seropositivity/*DIAGNOSIS/IMMUNOLOGY  HIV-1/*IMMUNOLOGY
       HIV-2/*IMMUNOLOGY  Immunoenzyme Techniques/*INSTRUMENTATION  Predictive
       Value of Tests  Quality Control  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).